Skip to content

Effect of Enzyme-containing Lozenge on Dental Biofilm Formation, Composition and Functionality

The Effect of Non-biocidal Adjuncts on the Formation, Composition, Functionality, and Microscale Architecture of Dental Biofilms: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06142409
Enrollment
34
Registered
2023-11-21
Start date
2023-08-17
Completion date
2024-02-25
Last updated
2025-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Biofilm Accumulation

Brief summary

A double-blind, placebo-controlled randomized cross-over trial evaluating the effect of enzyme-containing lozenge on in vivo and in situ grown dental biofilm accumulation. The study includes two phases, one each for the investigation of in-vivo and in-situ grown dental biofilm

Detailed description

Up to 50 subjects (aged ≥ 18 years old) with 3 or more active caries lesion, will be randomized to receive: Phase 1: The effect of multiple-enzyme treatment on plaque accumulation in vivo Phase 1 includes two experimental periods lasting for one day each, with a washout period of two weeks in between. Each experimental period will include two visits, at day 0 and day 1. At day 0, the participants will receive a professional tooth cleaning and be randomized to receive Sequence 1 or Sequence 2 in a double-blind randomized cross-over design: Sequence 1: 3 active enzyme-containing lozenges per day for one day (app. 24h) followed by a washout period of two weeks, followed by 3 identical placebo lozenges per day for one day (app. 24h). Sequence 2: 3 placebo lozenges per day for one day (app. 24h) followed by a washout period of two weeks, followed by 3 identical active enzyme lozenges per day for one day (app. 24h). The participants will be instructed to take one lozenge three times (morning, noon, evening) for one day. No normal oral hygiene procedures will be allowed during the intervention periods of one day. At the end of both experimental phases, plaque is assessed using planimetric recordings obtained with an intraoral camera and TM-QHPI to provide information on the individual level of plaque formation. Phase 2: The effect of multiple-enzyme treatment on in situ-grown biofilms The phase is designed in a double-blind randomized cross-over design, including two experimental periods lasting for 2 days, with a washout period of 5 days in between. Each experimental period will include two visits, on day 0 and day 2. Oral biofilms will be grown in situ on prefabricated non-fluorescent glass slabs for 48 hours. The glass slabs will be mounted on the individual lower-jaw splints. At day 0, the participants will be randomized to receive Sequence 1 or Sequence 2: Sequence 1: 3 active enzyme-containing lozenges per day for 2 days followed by a washout period of 5 days, followed by 3 identical placebo lozenges per day for 2 days. Sequence 2: 3 placebo lozenges per day for 2 days followed by a washout period of 5 days, followed by 3 identical active enzyme lozenges per day for 2 days. Oral biofilms will be grown in situ on prefabricated non-fluorescent glass slabs for 2-4 experimental periods of 48 hours. After each experimental period, the in situ-grown biofilms will be collected and stored in a research biobank.

Interventions

DIETARY_SUPPLEMENTEnzyme containing lozenge

Lozenge containing multiple enzyme combination

Sponsors

University of Aarhus
CollaboratorOTHER
Novozymes A/S
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males and females ≥ 18 years old. * Have three or more active carious lesions. * Anatomically possible to manufacture an intraoral lower-jaw splint. * Able to understand and follow instructions, as well as to read and sign the informed consent form. * A plaque index score ≥ 2 according to the Turesky Modification of the Quigley-Hein Plaque Index (TM-QHPI), following 8 to 12 hours plaque accumulation period.

Exclusion criteria

* History of allergies towards any of the ingredients in the test products * Self-reported pregnant or nursing * Antibiotic or anti-inflammatory medication within 90 days of the screening visit. * Orthodontic appliances, including retainers, or removable partial dentures. * Self-reported serious medical conditions

Design outcomes

Primary

MeasureTime frameDescription
Change in in-vivo dental biofilm accumulation1 dayTo investigate the effect of an enzyme-containing lozenge on dental biofilm accumulation in caries-active subjects in vivo assessed by the planimetric plaque index (PPI)

Secondary

MeasureTime frameDescription
Change in in-situ grown dental biofilm accumulation2 daysThe effect of enzyme-containing lozenge on changes in the microarchitecture of in situ-grown biofilms from caries-active subjects analyzed by optical coherence tomography.
Change in in-vivo dental biofilm accumulation1 daysTo investigate the effect of an enzyme-containing lozenge on dental biofilm accumulation in caries-active subjects in vivo assessed by the Turesky-modified Quigley Hein Plaque Index (TM-QHPI)
Change in oral microbial community composition of in-situ grown dental biofilm2 daysShift in oral microbial community composition of in situ-grown biofilms from caries-active subjects assessed by next-generation sequencing of 16S rRNA genes

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026